Complement components and ligands

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K D of 7.9 nM. LNP023 inhibits factor B with an IC 50 value of

NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC 50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.Form:Solid

NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC 50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.Form:Solid

NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC 50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.Form:Solid

NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC 50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.Form:Solid

NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC 50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.Form:Solid

Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC 50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for